FDA "B" List For Cosmetics Priorities Includes Adverse Event Monitoring
This article was originally published in The Rose Sheet
Executive Summary
Office of Cosmetics & Colors Director John Bailey, PhD, included cosmetics adverse reaction monitoring as part of the office's "B" List for priority activities in 1999. Bailey spoke during a Cosmetic, Toiletry Fragrance Association-sponsored "Meet the Regulators" conference in Bethesda, Md. Feb. 2.
You may also be interested in...
CFSAN priorities
FDA requests public comment on the Center for Safety & Applied Nutrition's program priorities for 2000 in an announcement published in the Federal Register Sept. 1. Comments are due Sept. 30. CFSAN's 1999 "A" priority list includes reinstating the Voluntary Cosmetic Registration Program and completing the safety assessment and review of alpha hydroxy acids and diethanolamine (1"The Rose Sheet" Feb. 1, p. 7). Among goals on the Office of Cosmetics & Colors' priority "B" list in 1999 is issuing a report on adverse reactions (2"The Rose Sheet" Feb. 8, p. 6)
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program